News

Gocovri (amantadine) extended release oral capsules provided long-term improvements of motor complications in Parkinson’s disease patients, according to results from a Phase 3 clinical trial. Gocovri, developed by Adamas Pharmaceuticals, is the only medication approved by the U.S. Food and Drug Administration for the treatment of dyskinesia — involuntary, jerky movements…

A new brain scanner, which is 10 times less expensive and much smaller than current models, has the potential to significantly improve the diagnosis of dementia linked to neurodegenerative diseases, such as Parkinson’s disease, Alzheimer’s, and amyotrophic lateral sclerosis (ALS). The scanner, which uses Positron Emission Tomography (PET) imaging, is…

Sonde Health’s vocal biomarker technology being developed to potentially diagnose and monitor mental and physical disorders, including Parkinson’s disease, has recently been issued patents in the U.S. and Australia. Patent No. 9,936,914, issued by the U.S. Patent and Trademark Office, provides coverage until 2032, and patent No.

The mechanisms that lead to progressive degenerative diseases like Parkinson’s in adulthood begin much earlier than previously thought, a mouse study suggests. In fact, they may start soon after birth, researchers said. The study, “Mutant ataxin1 disrupts cerebellar development in spinocerebellar ataxia type 1,” was published in the Journal…

Anavex Life Sciences is planning to open a Phase 2 clinical trial testing Anavex 2-73, a potential oral treatment for patients with Parkinson’s disease dementia (PDD), this year. Anavex 2-73 aims to treat PDD by binding to the sigma-1 receptor, located in a cellular structure called the endoplasmic reticulum…

Computers may be taught to identify features in nerve cells that have not been stained or undergone other damaging treatments for microscope use, an approach with the potential to revolutionize the way researchers study neurodegenerative diseases such as Parkinson’s. “Researchers are now generating extraordinary amounts of data. For neuroscientists, this means…

Nuplazid (pimavanserin) is well-tolerated and can lead to clinical improvement in people with Parkinson’s disease psychosis (PDP), according to the results of studies into its real-life use. Acadia will present these data at the 2018 American Academy of Neurology ANN Annual Meeting, taking place in Los Angeles from…

Global Kinetics Corporation has obtained $350,000 in foundation funding to conduct a global clinical trial of its wearable device for recording Parkinson’s patients’ movement information. In addition to tracking movement, the watch-like Personal KinetiGraph reminds patients to take their medication and records when they do. The…

Parkinson’s treatment candidate BIIB054 was well-tolerated and had a favorable pharmacological profile in preliminary Phase 1 clinical results. Biogen will present those results at the 2018 American Academy of Neurology ANN Annual Meeting in Los Angeles, California, April 21-27. Parkinson’s News Today will be covering the conference. The presentation “Randomized, Double-Blind,…

Human neural stem cells show promise as therapy for Parkinson’s disease, according to six-month interim results of Phase 1 trial. The therapy’s developer, International Stem Cell’s Corporation subsidiary Cyto Therapeutics, will present the results at the American Academy of Neurology annual meeting in Los Angeles, April 21-27. Parkinson’s News Today will be…